News

Trump won't force Medicaid to cover GLP-1s for obesity. A few states are doing it anyway.
South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Healio1d
Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’
Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity Medicine 2025.The use of GLP-1 receptor agonists and other weight-loss medications ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...
Are weight loss drugs safe? Learn some of the side effects
The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...